Home Tags Bayer

Tag: Bayer

Anetumab Ravtansine does not meet Primary Endpoint in Second-Line Mesothelioma

A Phase II clinical trial evaluating its anetumab ravtansine, also known as BAY 949343, as a monotherapy in patients with recurrent malignant pleural mesothelioma...

Bayer uses Progenics’ PSMA Antibody Technology for the Development of Alpha-Radiolabeled...

Progenics Pharmaceuticals, Inc. (Tarrytown, NY), has granted an exclusive license to Bayer for the development and commercialization of therapeutic antibodies combining the Progenics's prostate specific...

London Calling: The Cutting-edge of Novel ADC Technologies

Major players in the rapidly advancing field of antibody drug conjugates (ADCs) will meet in London, United Kingdom, on 23-24 May for the annual...

X